Torsades de pointes with administration of high-dose intravenous d- sotalol to a patient with congestive heart failure

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 830-831

  Gottlieb, Stephen S ^a,b   Cines, Michelle ^a,b   Marshall, Joanne ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; SOTALOL;

AGED; ARTICLE; CARDIOVERSION; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MALE; SOTALOL; TORSADES DE POINTES;

EID: 0030818877     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gottlieb SS, Singh S, Munger M, Eichhorn EJ, Ilgenfritz J, Hanyok J. Hemodynamic effects of the class III antiarrhythmic drug d-sotalol, in patients with congestive heart failure. Am J Cardiol 1996;78:1411-15.
2. Soyka, LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65:74A-81.
3. Tham TCK, MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J Cardiovasc Pharmacol 1993;21:507-12.
4. Spence SG, Vetter C, Hoe CM. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994;49:282-92.
5. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A-50.
6. Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJ. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 1995;91:864-72.
7. Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol; therapy in patients treated for sustained VT/VF [abstr]. Pace 1992, 15:551.
8. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J. Cardiol 1993;72:44B-9.
9. Woosley RL, Sale M. QT interval: a measure of drug action. Am J Cardiol 1993;72:36B-43.
10. Brachmann J, Schmitt C, Schols W, et al. Acute antiarrhythmic efficacy of i.v. and oral d-sotalol in patients with sustained ventricular arrhythmias [abstr]. J Am Coll Cardiol 1992;19:244A.
11. Poirier JM, Jaillon P, Lecocq V, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Eur J Clin Pharmacol 1990;38:579-82.
12. Woosley RL. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. Am Heart J 1987;114:1280-91.